Despite being a comparatively quiet month, June nonetheless produced a handful of significantly impactful clinical data and drug approvals. The US Food and Drug Administration (FDA) accepted and granted Priority Review to mavacamten in adolescents, as well as approved olezarsen for severe hypertriglyceridemia. On the conference side, an updated analysis of VESALIUS-CV has revealed evolocumab’s ability to reduce cardiovascular events. At the same time, new guidelines from the American College of Cardiology and the American Heart Association provide clinicians with a more direct approach to diagnosing and managing cardiovascular-metabolic-kidney (CKM) syndrome.
